Pfizer and BioNTech biopharmaceutics announced today a $1.95 billion dollar agreement with the U.S. government for 100 million doses of the partnership's BNT162 program vaccine.
As manufacturers worldwide race to develop the first viable COVID-19 vaccine faster than any vaccine ever developed in human history, late November remains an important date in the United States to vaccinate a large number of Americans.
COVIDVax.news regularly monitors leading vaccine manufacturers for updates on their vaccine development. Here is a chart and summary of progress today.
We spoke with Pfizer today and confirmed October remains feasible but is contingent on successful aquisition of an Emergency Use Declaration